Home-based app-guided exercise program versus health education to boost activity in people with non-muscle invasive bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants with non-muscle invasive bladder cancer who are currently insufficiently active are randomized to one of two groups for 12 weeks. The intervention group uses the ExerciseRx app for personalized home exercise sessions and gradually increasing daily step goals, while the comparison group receives health education materials; all participants wear a Fitbit to track activity. The app adapts goals based on progress, provides feedback, and offers exercise videos and motivational nudges. Outcomes focus on changes in physical activity with a follow-up visit four weeks after the intervention ends.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (age \>= 18 years)
* Prior diagnosis of non-muscle invasive bladder cancer (NMIBC), currently on surveillance or receiving maintenance intravesical therapy (including intravesical chemotherapy, immunotherapy)
* Classified as insufficiently active on the Physical Activity as a Vital Sign (PAVS) assessment
* Has an Android or Apple Smartphone/Tablet
* Ambulatory
* English-speaking
* Willing and able to participate in study activities and sign the informed consent form

Exclusion Criteria:

* Severe cognitive or memory impairment/dementia precluding ability to follow instructions or participate in survey assessments
* Inability to read or understand English
* Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria to run the ExerciseRx app
* Not receiving treatment at University of Washington (UW)
* Orthopedic, neurologic, or other problems that prevent safe ambulation and protocol adherence. Information on prior falls and other recent orthopedic or neurologic problems will be used to make judgment about protocol eligibility
* Inability/Unwillingness to participate in a personalized exercise program
* Current diagnosis with muscle-invasive or metastatic bladder cancer
* Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria for using the ExerciseRx app
* Participation in a clinical trial that does not permit enrollment in the EMPOWER trial

Where it's running

• Fred Hutch/University of Washington Cancer Consortium
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Sarah Psutka, MD, MSc — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: Sarah Psutka, MD, MSc
• Email: spsutka@uw.edu
• Phone: 206-210-4040

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In-home chemotherapy for bladder cancer treatment

  This study tests whether giving chemotherapy for bladder cancer at home is safe and more convenient for patients compared to getting it in a clinic.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT06704191

• Treatment for recurrent or refractory non-muscle invasive bladder cancer using targeted nanoparticles

  This study is testing a new treatment using special nanoparticles to see if it can help people with recurring bladder cancer feel better and improve their chances of staying cancer-free.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT06173349

• Adding gemcitabine to BCG for people with recurrent non‑muscle invasive bladder cancer.

  This phase III test tries whether giving intravesical gemcitabine alongside BCG helps people whose non‑muscle invasive bladder cancer has come back after prior BCG.

  Recruiting at 60 sites Phase 3 Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 59 other locations · NCT07000084

• Combining pembrolizumab with radiation therapy for bladder cancer treatment

  This study is testing if combining the immunotherapy drug pembrolizumab with radiation therapy can help people with non-muscle invasive bladder cancer do better than standard chemotherapy during treatment.

  Recruiting at 135 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 146 other locations · NCT06770582

• Cruciferous vegetable eating program to reduce recurrence and progression in early-stage bladder cancer

  This trial will test whether a behavioral program that increases cruciferous vegetable intake (like broccoli, cabbage, kale) and a maintenance component can lower recurrence or progression in adults with early-stage non-muscle invasive bladder cancer.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT06733363

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.